Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632375 | 0.92 | LRRK2 (0.51) | HRH3MAPK10LRRK2JAK2 | |
| SCHEMBL1633497 | 0.89 | MAPK10 (0.50) | MAPK10LRRK2JAK2 | |
| SCHEMBL1633947 | 0.87 | MAPK10 (0.58) | HRH3MAPK10LRRK2JAK2 | |
| SCHEMBL12764495 | 0.87 | MAPK10 (0.51) | MAPK10LRRK2JAK2 | |
| SCHEMBL1634193 | 0.80 | BRD4 (0.41) | HRH3JAK2 | |
| SCHEMBL12764745 | 0.80 | MAPK10 (0.59) | MAPK10LRRK2JAK2 | |
| SCHEMBL1633501 | 0.79 | LRRK2 (0.51) | MAPK10LRRK2JAK2 | |
| SCHEMBL1632952 | 0.79 | LRRK2 (0.54) | MAPK10LRRK2JAK2 | |
| SCHEMBL13498322 | 0.79 | LRRK2 (0.51) | MAPK10LRRK2JAK2 | |
| SCHEMBL1633387 | 0.78 | LRRK2 (0.54) | HRH3MAPK10LRRK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | HRH3 3514/4885MAPK10 402/4885LRRK2 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.